Concepedia

Pol Specenier

PS

39

Publications

3.1K

Citations

23

H-Index

1998

Active since

Affiliations

Antwerp University Hospital(Current)

Cliniques Universitaires Saint-Luc

Institut Jules Bordet

KU Leuven

University of Antwerp

Pol Specenier is an author at Antwerp University Hospital specializing in oncology, medicine, and radiation oncology.

ORCID

Top concepts

Publications per year

1998–2024

39

Publications

39

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.6K citations · Full text

, , +5

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

Alba A. Brandes, Santosh Kesari, Juan Manuel Sepúlveda-Sánchez et al. · Neuro-Oncology · 2016 · 264 citations · Full text

Tipifarnib in Head and Neck Squamous Cell Carcinoma With<i>HRAS</i>Mutations

Alan L. Ho, Irene Braña, Robert I. Haddad et al. · Journal of Clinical Oncology · 2021 · 186 citations · Full text

Cetuximab: its unique place in head and neck cancer treatment

J. Vermorken, Pol Specenier · Biologics · 2013 · 102 citations · Full text

Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins

Carolien Boeckx, Ken Op de Beeck, An Wouters et al. · Cancer Letters · 2014 · 61 citations

, , +5

Rows per page

1–5 of 39